Inhibition of TGFβ signaling in cancer therapy

Carlos L. Arteaga

doi:10.1016/j.gde.2005.12.009

Inhibition of TGFβ signaling in cancer therapy

Carlos L. Arteaga

Research output: Contribution to journal › Review article › peer-review

109 Scopus citations

Abstract

Recent evidence continues to support a central role for TGFβ in tumor maintenance and progression. Although this may involve TGFβ-mediated paracrine effects that modulate the tumor microenvironment and the host immune system, some studies causally implicate autocrine TGFβ in cancer cell motility and survival. Other recent evidence indicates synergy between oncogene and TGFβ signaling in epithelial cell transformation. This suggests opportunities for dissecting molecular mechanisms of cross-talk as well as providing insights into possible combinatorial molecular anticancer therapies that will include TGFβ inhibitors.

Original language	English (US)
Pages (from-to)	30-37
Number of pages	8
Journal	Current Opinion in Genetics and Development
Volume	16
Issue number	1
DOIs	https://doi.org/10.1016/j.gde.2005.12.009
State	Published - Feb 2006

ASJC Scopus subject areas

Genetics
Developmental Biology

Access to Document

10.1016/j.gde.2005.12.009

Cite this

@article{39da772e9c844ef5970058da526d00b8,

title = "Inhibition of TGFβ signaling in cancer therapy",

abstract = "Recent evidence continues to support a central role for TGFβ in tumor maintenance and progression. Although this may involve TGFβ-mediated paracrine effects that modulate the tumor microenvironment and the host immune system, some studies causally implicate autocrine TGFβ in cancer cell motility and survival. Other recent evidence indicates synergy between oncogene and TGFβ signaling in epithelial cell transformation. This suggests opportunities for dissecting molecular mechanisms of cross-talk as well as providing insights into possible combinatorial molecular anticancer therapies that will include TGFβ inhibitors.",

author = "Arteaga, {Carlos L.}",

note = "Funding Information: Supported in part by NIH R01 grants CA62212 and CA80195, Breast Cancer Specialized Program of Research Excellence (SPORE) Grant P50 CA98131, and Vanderbilt-Ingram Comprehensive Cancer Center Support Grant P30 CA68485 ",

year = "2006",

month = feb,

doi = "10.1016/j.gde.2005.12.009",

language = "English (US)",

volume = "16",

pages = "30--37",

journal = "Current Opinion in Genetics and Development",

issn = "0959-437X",

publisher = "Elsevier Limited",

number = "1",

}

TY - JOUR

T1 - Inhibition of TGFβ signaling in cancer therapy

AU - Arteaga, Carlos L.

N1 - Funding Information: Supported in part by NIH R01 grants CA62212 and CA80195, Breast Cancer Specialized Program of Research Excellence (SPORE) Grant P50 CA98131, and Vanderbilt-Ingram Comprehensive Cancer Center Support Grant P30 CA68485

PY - 2006/2

Y1 - 2006/2

N2 - Recent evidence continues to support a central role for TGFβ in tumor maintenance and progression. Although this may involve TGFβ-mediated paracrine effects that modulate the tumor microenvironment and the host immune system, some studies causally implicate autocrine TGFβ in cancer cell motility and survival. Other recent evidence indicates synergy between oncogene and TGFβ signaling in epithelial cell transformation. This suggests opportunities for dissecting molecular mechanisms of cross-talk as well as providing insights into possible combinatorial molecular anticancer therapies that will include TGFβ inhibitors.

AB - Recent evidence continues to support a central role for TGFβ in tumor maintenance and progression. Although this may involve TGFβ-mediated paracrine effects that modulate the tumor microenvironment and the host immune system, some studies causally implicate autocrine TGFβ in cancer cell motility and survival. Other recent evidence indicates synergy between oncogene and TGFβ signaling in epithelial cell transformation. This suggests opportunities for dissecting molecular mechanisms of cross-talk as well as providing insights into possible combinatorial molecular anticancer therapies that will include TGFβ inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=30644467227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30644467227&partnerID=8YFLogxK

U2 - 10.1016/j.gde.2005.12.009

DO - 10.1016/j.gde.2005.12.009

M3 - Review article

C2 - 16377175

AN - SCOPUS:30644467227

SN - 0959-437X

VL - 16

SP - 30

EP - 37

JO - Current Opinion in Genetics and Development

JF - Current Opinion in Genetics and Development

IS - 1

ER -

Inhibition of TGFβ signaling in cancer therapy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this